Recent findings from preclinical trials involving HIF-2α inhibitors and animal models indicate that ccRCC carcinogenesis is not exclusively attributed to HIF-2α, but rather involves collaboration with HIF-1α, potentially other pVHL targets, and additional mutated proteins. Here, VHL is linked to nonpapillary renal cell carcinoma.